Abstract
INTRODUCTION: Serum carcinoembryonic antigen is used mainly for tumor follow-up to detect recurrence of colonic cancer. However, raised preoperative carcinoembryonic antigen levels may be helpful for the identification of understaged cases and of patients meriting more intensive preoperative and postoperative diagnostic workup. METHODS: From a prospectively collected database, the data on 261 patients who had curative colonic carcinoma with a minimal follow-up of five years and who had preoperative carcinoembryonic antigen levels assessed were retrieved and analyzed. Outcome parameters were local and/or distant recurrence and time to recurrence. These parameters were correlated with Dukes staging and preoperative carcinoembryonic antigen levels. RESULTS: The cumulative diseasefree survival of patients with a preoperative carcinoembryonic antigen level within the normal range was significantly better than that of those whose carcinoembryonic antigen was 5 ng/ml or more (P=0.001). No patient with carcinoembryonic antigen levels less than 1 ng/ml developed metastatic recurrence. Twenty-three percent of all patients with a raised carcinoembryonic antigen above 5 ng/ml compared with 2.1 percent of patients with carcinoembryonic antigen below 5 ng/ml developed a metastasis at two years. At five years, these figures were 37.2 percent and 7.5 percent, respectively. Dukes staging and carcinoembryonic antigen levels were found to be directly correlated (P<0.001) when all patients were included. Carcinoembryonic antigen of more of 15 ng/ml was found to be a significant adverse prognostic indicator for disease-free survival irrespective of Dukes staging (P<0.02). Raised carcinoembryonic antigen levels predicted distant metastatic recurrence (P<0.001) but did not predict local recurrence (P=0.72). CONCLUSIONS: High preoperative carcinoembryonic antigen levels above 15 ng/ml predicted an increased risk of metastatic recurrence in potentially curative colonic cancer and may indicate undetectable disseminated disease. Preoperative carcinoembryonic antigen levels predict understaging and the possibility of distant recurrence. Such patients may therefore be selected for adjuvant therapy where indicated. Therefore, carcinoembryonic antigen is complementary to conventional Dukes staging for the prediction of recurrence and survival.
Similar content being viewed by others
References
Gold P, Freedman SO. Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121:439–62.
Gordon PH. Malignant neoplasm of the colon. In: Gordon PH, Nivatvong S, eds. Principles and practice of surgery for the colon, rectum, and anus. St. Louis: Quality Medical Publishing, 1992:501–77.
Herrera MA, Chu TM, Holyoke ED. Carcinoembryonic antigen (CEA) as a prognostic and monitoring test in clinically complete resection of colorectal carcinoma. Ann Surg 1976;183:5–9.
Wanebo HJ, Rao B, Pinsky CM,et al. Preoperative carcino-embryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978;299:448–51.
Chapman MA, Buckley D, Henson DB, Armitage NC. Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer. Br J Cancer 1998;78:1346–9.
Moertel CG, Judith R, Fallon O,et al. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 1986;58:603–10.
Prado IB, Laudanna AA, Carneiro CR. Susceptibility of colorectal-carcinoma cells to natural-killer-mediated lysis: relationship to CEA expression and degree of differentiation. Int J Cancer 1995;61:854–60.
Kim JC, Roh SA, Park KC. Adhesive function of carcinoembryonic antigen in the liver metastasis of KM-12c colon carcinoma cell line. Dis Colon Rectum 1997;40:946–53.
Hosteller RB, Augustus LB, Mankarious R,et al. Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. J Natl Cancer Inst 1990;82:380–5.
Von Kleist S, Migule I, Halla B. Possible function of CEA as cell-contact inhibitory molecule. Anticancer Res 1995;15:1889–94.
Stanners CP, DeMarte L, Rojas M, Gold P, Fuks A. Opposite function for two classes of genes of the human carcinoembryonic antigen family. Tumour Biol 1995;16:23–31.
Kim JC, Han MS, Lee HK,et al. Distribution of carcinoembryonic antigen and biologic behavior in colorectal carcinoma. Dis Colon Rectum 1999;42:640–8.
Milburn J. Tumor markers: prognostic and therapeutic implications. In: Wanebo HJ, ed. Colorectal cancer. St Louis: Mosby-Year Book, 1993;106–129.
Cullen KJ, Stevens DP, Frost MA,et al. Carcinoembryonic antigen (CEA), smoking and cancer in a longitudinal population study. Aust N Z J Med 1976;6:279–83.
Doos WG, Wolff WI, Shinya H,et al. CEA levels in patients with colorectal polyps. Cancer 1975;36:1996–2003.
Loewenstein MS, Zamcheck N. Carcinoembryonic antigen (CEA) levels in benign gastrointestinal disease states. Cancer 1978;42:1412–18.
Filella X, Molina R, Pique JM,et al. CEA as a prognostic factor in colorectal cancer. Anticancer Res 1994;14:705–8.
Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum 1994;37:272–7.
Harrison LE, Guillem JG, Paty P, Cohen AM. Preoperative carcinoembryonic antigen outcomes in nodenegative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 1997;185:55–9.
Author information
Authors and Affiliations
About this article
Cite this article
Wiratkapun, S., Kraemer, M., Seow-Choen, F. et al. High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: Results of a five-year study. Dis Colon Rectum 44, 231–235 (2001). https://doi.org/10.1007/BF02234298
Issue Date:
DOI: https://doi.org/10.1007/BF02234298